These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 17971091)

  • 21. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
    Foster GR; Fried MW; Hadziyannis SJ; Messinger D; Freivogel K; Weiland O
    Scand J Gastroenterol; 2007 Feb; 42(2):247-55. PubMed ID: 17327945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
    Ferenci P; Brunner H; Laferl H; Scherzer TM; Maieron A; Strasser M; Fischer G; Hofer H; Bischof M; Stauber R; Gschwantler M; Steindl-Munda P; Staufer K; Löschenberger K;
    Hepatology; 2008 Jun; 47(6):1816-23. PubMed ID: 18454510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.
    Prati D; Shiffman ML; Diago M; Gane E; Rajender Reddy K; Pockros P; Farci P; O'Brien CB; Lardelli P; Blotner S; Zeuzem S
    J Hepatol; 2006 Apr; 44(4):679-85. PubMed ID: 16487620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.
    De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Raiteri R; Di Perri G
    J Antimicrob Chemother; 2006 Feb; 57(2):360-3. PubMed ID: 16396921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
    Reddy KR; Shiffman ML; Morgan TR; Zeuzem S; Hadziyannis S; Hamzeh FM; Wright TL; Fried M
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):124-9. PubMed ID: 17196435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus with normal transaminase levels.
    Puoti C
    Dig Dis; 2007; 25(3):277-8. PubMed ID: 17827956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.
    Dusheiko G; Main J; Thomas H; Reichard O; Lee C; Dhillon A; Rassam S; Fryden A; Reesink H; Bassendine M; Norkrans G; Cuypers T; Lelie N; Telfer P; Watson J; Weegink C; Sillikens P; Weiland O
    J Hepatol; 1996 Nov; 25(5):591-8. PubMed ID: 8938532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.
    Zeuzem S; Alberti A; Rosenberg W; Marcellin P; Diago M; Negro F; Prati D; Puoti C; Roberts SK; Shiffman ML
    Aliment Pharmacol Ther; 2006 Oct; 24(8):1133-49. PubMed ID: 17014573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon therapy for hepatitis C.
    Trépo C; Habersetzer F; Bailly F; Berby F; Pichoud C; Berthillon P; Vitvitski L
    Antiviral Res; 1994 Jul; 24(2-3):155-63. PubMed ID: 7979315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum ALT: tarnished gold standard for interferon response in hepatitis C virus infection.
    Yee HF; Wright TL
    Hepatology; 1994 Jun; 19(6):1531-3. PubMed ID: 8188185
    [No Abstract]   [Full Text] [Related]  

  • 34. Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C.
    Saab S; Hu R; Ibrahim AB; Goldstein LI; Kunder G; Durazo F; Han S; Yersiz H; Ghobrial RM; Farmer DG; Busuttil RW; Lassman C
    Am J Transplant; 2003 Mar; 3(3):328-33. PubMed ID: 12614290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α-fetoprotein levels.
    Kajiwara E; Ooho A; Yamashita N
    Hepatol Res; 2012 Mar; 42(3):254-63. PubMed ID: 22136198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The genotype distribution of hepatitis C in southeastern Taiwan: Clinical characteristics, racial difference, and therapeutic response.
    Cheng CH; Chen HL; Lin IT; Wu CH; Lee YK; Wong MW; Bair MJ
    Kaohsiung J Med Sci; 2015 Nov; 31(11):597-602. PubMed ID: 26678941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical management of HCV carriers with normal aminotransferase levels.
    Puoti C; Guido M; Mangia A; Persico M; Prati D;
    Dig Liver Dis; 2003 May; 35(5):362-9. PubMed ID: 12846410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 'new normal': Harnessing the experience of COVID-19 for sustained improvements in global emergency care.
    Mitchell R; Nou G
    Lancet Reg Health West Pac; 2020 Aug; 1():100012. PubMed ID: 34173595
    [No Abstract]   [Full Text] [Related]  

  • 39. Erratum:
    Postgrad Med J; 2017 Apr; 93(1098):236. PubMed ID: 28331013
    [No Abstract]   [Full Text] [Related]  

  • 40. Facing the 'new normal' through cooperation and collaboration: a response to Corpuz.
    Cordero DA
    J Public Health (Oxf); 2021 Sep; 43(3):e519. PubMed ID: 34050363
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.